Gliptins and Cardiovascular Outcomes: A Comparative and Critical Analysis after TECOS

Table 6

Saxagliptin polled phase 2b/3 MACE [13].

	Events (%): saxagliptin/placebo	OR (95% CI)
Sponsor MACE	0.5/1	0.5 (0.2–1.2)
Custom MACE (ST)	0.1/0.6	0.21 (0.04–0.8)
Custom MACE (ST + LT)	0.7/1.3	0.52 (0.3–1.0)
SMQ MACE (ST)	1.8/2.0	0.90 (0.6–1.5)
SMQ MACE (ST + LT)	3.1/3.2	0.96 (0.7–1.4)